240 related articles for article (PubMed ID: 26952011)
1. Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels.
Huang Z; Liang L; Li L; Xu M; Li X; Sun H; He S; Lin L; Zhang Y; Song Y; Yang M; Luo Y; Loh HH; Law PY; Zheng D; Zheng H
Lipids Health Dis; 2016 Mar; 15():47. PubMed ID: 26952011
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose.
Sutou I; Nakatani T; Hashimoto T; Saito Y
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):161-5. PubMed ID: 26095488
[TBL] [Abstract][Full Text] [Related]
4. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
5. Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain.
Hayashi T; Ikehata S; Matsuzaki H; Yasuda K; Makihara T; Futamura A; Arakawa Y; Kuki R; Fukuura K; Takahashi H; Mori N; Higashiguchi T; Yamadaa S
Biol Pharm Bull; 2014; 37(12):1860-5. PubMed ID: 25590058
[TBL] [Abstract][Full Text] [Related]
6. Opioid Rotation in Cancer Pain Treatment.
Schuster M; Bayer O; Heid F; Laufenberg-Feldmann R
Dtsch Arztebl Int; 2018 Mar; 115(9):135-142. PubMed ID: 29563006
[TBL] [Abstract][Full Text] [Related]
7. Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
Chapman CR; Bradshaw DH
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):370-7. PubMed ID: 24143927
[TBL] [Abstract][Full Text] [Related]
8. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
10. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study.
Fernandes K; Martins D; Juurlink D; Mamdani M; Paterson JM; Spooner L; Singh S; Gomes T
PLoS One; 2016; 11(12):e0167479. PubMed ID: 27973601
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
14. Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain.
Heiskanen T; Langel K; Gunnar T; Lillsunde P; Kalso EA
J Pain Symptom Manage; 2015 Oct; 50(4):524-32. PubMed ID: 25242020
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of multimodal pain management after bipolar hemiarthroplasty for hip fracture: a randomized, controlled study.
Kang H; Ha YC; Kim JY; Woo YC; Lee JS; Jang EC
J Bone Joint Surg Am; 2013 Feb; 95(4):291-6. PubMed ID: 23302898
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.
Sima L; Fang WX; Wu XM; Li F
J Clin Pharm Ther; 2012 Feb; 37(1):27-31. PubMed ID: 21208247
[TBL] [Abstract][Full Text] [Related]
17. Morphine and hydromorphone-induced hyperalgesia in a hospice patient.
Juba KM; Wahler RG; Daron SM
J Palliat Med; 2013 Jul; 16(7):809-12. PubMed ID: 22925158
[TBL] [Abstract][Full Text] [Related]
18. Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Hanks GW; Conno F; Cherny N; Hanna M; Kalso E; McQuay HJ; Mercadante S; Meynadier J; Poulain P; Ripamonti C; Radbruch L; Casas JR; Sawe J; Twycross RG; Ventafridda V;
Br J Cancer; 2001 Mar; 84(5):587-93. PubMed ID: 11237376
[TBL] [Abstract][Full Text] [Related]
19. Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Zin CS; Rahman NA; Ismail CR; Choy LW
Pain Pract; 2017 Jul; 17(6):774-781. PubMed ID: 27676695
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
